Advertisement

Topics

Search Results for "Rna Interference Patents Dr Allen"

14:48 EDT 28th June 2016 | BioPortfolio

Matching Channels

Biosuperior Antibodies

After biosimilar versions of therapeutic proteins have become reality in Europe and in the US, now it’s the turn of therapeutic antibodies to be in the line of fire. Patents of the first wave of...

Tumor Necrosis Factor TNF Products

Tumor Necrosis Factor (TNF) and TNF receptor antagonists and agonists used to treat TNF-mediated inflammatory diseases such as rheumatoid arthritis or to treat cancer. TNF blockers are the commerc...

Coagulation Factors

Fourteen different blood coagulation factors are present in the body. Each plays a crucial role in the process described above. Some work to increase the activity level of the other factors while so...

Matching News

Paul G. Allen announces $100 million to launch the Paul G. Allen Frontiers Group

(Allen Institute) Philanthropist and entrepreneur Paul G. Allen today announced an initial commitment of $100 million to create The Paul G. Allen Frontiers Group, whose purpose will be to explore the ...

The Patent Dispute Over Gene Editing Technologies: The Broad Institute, Inc. vs. The Regents of the University of California

The patent dispute already called “the biggest in biotech history” is only getting started. On January 11, 2016, Administrative Law Judge (ALJ) Deborah Katz officially declared an interference ove...

Paul Allen Announces Funding for Research at the Frontiers of Bioengineering and Systems Biology

Bio-IT World | Paul Allen, the co-founder of Microsoft and a lavish philanthropist in the life sciences, has made a $100 million commitment to a new scientific grant program, the Paul G. Allen Fr...

CRISPR Patent Investigation to Begin

The US Patent and Trademark Office is set to launch its “patent interference” inquiry into the competing patents on the gene-editing technology.

Paul G. Allen Frontiers Group to launch for ‘out-of-the-box’ research

Philanthropist and entrepreneur Paul G. Allen has announced an initial commitment of $100 million to create The Paul G. Allen Frontiers Group, whose purpose will be to explore the landscape of bios...

#news #biotech Microsoft co-founder Paul Allen launches $100M bioscience fund

// The Paul G. Allen Frontiers Group has officially launched today as the life sciences funding arm of the Allen Institute. The Group, headquartered in Seattle, WA, has been set up by the multi-millio...

IARPA awards $18.7M contract to Allen Institute to reconstruct neuronal connections

(Allen Institute) The Intelligence Advanced Research Projects Activity (IARPA) has awarded an $18.7 million contract to the Allen Institute for Brain Science, as part of a larger project with Baylor C...

PTAB declares interference in CRISPR dispute

The Patent Trial and Appeal Board of the U.S. Patent and Trademark Office declared an interference in an ongoing dispute over ownership of IP related to gene editing technology CRISPR/Cas9 (

Matching PubMed Articles

Novel methods to optimize the effects of transcranial direct current stimulation: a systematic review of transcranial direct current stimulation patents.

Transcranial direct current stimulation (tDCS) is a neuromodulatory technique that has been extensively studied. While there have been initial positive results in some clinical trials, there is still ...

Extending the market exclusivity of therapeutic antibodies through dosage patents.

Dosage patents are one way to extend the market exclusivity of an approved drug beyond the lifetime of the patent that protects the drug as such. Dosage patents may help to compensate the applicant fo...

Searching bioremediation patents through Cooperative Patent Classification (CPC).

Patent classification systems have traditionally evolved independently at each patent jurisdiction to classify patents handled by their examiners to be able to search previous patents while dealing wi...

FFA4/GPR120 agonists: a survey of the recent patent literature.

FFA4/GPR120, a member of the rhodopsin family of G-protein-coupled receptors (GPCRs), is becoming an important target for therapeutic intervention in several areas of disease, including metabolic dise...

Big Data from Pharmaceutical Patents: A Computational Analysis of Medicinal Chemists' Bread and Butter.

Multiple recent studies have focused on unraveling the content of the medicinal chemist's toolbox. Here, we present an investigation of chemical reactions and molecules retrieved from US patents over ...

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement